作者
Cyrus Chargari,Pauline Maury,Matthieu Texier,Catherine Genestie,Philippe Morice,Sophie Bockel,Sébastien Gouy,Mouhamadou Bachir Bâ,S. Achkar,François Lux,Olivier Tillement,Sandrine Dufort,Géraldine Le Duc,Olivier Debeaumont,Christophe Massard,Amandine Maulard,Erika Porcel,Ratislav Bahleda,Samy Ammari,Daphné Morel,Sophie Espenel,Patricia Pautier,Charlotte Robert,Éric Deutsch
摘要
Activated guided irradiation by X-ray (AGuIX) nanoparticles are gadolinium-based agents that have the dual benefit of mimicking the effects of a magnetic resonance imaging (MRI) contrast agent used in a clinical routine and enhancing the radiotherapeutic activity of conventional X-rays (for cancer treatment). This "theragnostic" action is explained on the one hand by the paramagnetic properties of gadolinium and on the other hand by the generation of high densities of secondary radiation following the interaction of ionizing radiation and high-Z atoms, which leads to enhanced radiation dose deposits within the tumors where the nanoparticles accumulate. Here, we report the results of a phase I trial that aimed to assess the safety and determine the optimal dose of AGuIX nanoparticles in combination with chemoradiation and brachytherapy in patients with locally advanced cervical cancer. AGuIX nanoparticles were administered intravenously and appropriately accumulated within tumors on a dose-dependent manner, as assessed by T